HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.

AuthorsNiels W C J van de Donk, Tineke Casneuf, Alessandro Di Cara, Paul W Parren, Sonja Zweegman, Berris van Kessel, Henk M Lokhorst, Saad Z Usmani, Sagar Lonial, Paul G Richardson, Christopher Chiu, Tuna Mutis, Inger S Nijhof, A Kate Sasser
JournalBritish journal of haematology (Br J Haematol) Vol. 184 Issue 3 Pg. 475-479 (02 2019) ISSN: 1365-2141 [Electronic] England
PMID29411874 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • FCGR2A protein, human
  • FCGR2B protein, human
  • Neoplasm Proteins
  • Receptors, IgG
  • daratumumab
Topics
  • Antibodies, Monoclonal (administration & dosage, adverse effects)
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Multiple Myeloma (drug therapy, genetics, mortality)
  • Neoplasm Proteins (genetics)
  • Polymorphism, Genetic
  • Receptors, IgG (genetics)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: